Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tevogen Bio Holdings Inc.

Get SEC filing alerts via email and in your feed for Tevogen Bio Holdings Inc.

TVGN TVGNW

Tevogen Bio Holdings Inc.

About Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. develops off-the-shelf, allogeneic T cell therapies targeting infectious diseases and cancers. Its ExacTcell technology harnesses naturally occurring CD8+ cytotoxic T lymphocytes to create precise, multi-target immune treatments. The company's lead product, TVGN 489, aims to treat COVID-19, Long COVID, and related conditions, offering rapid, scalable, and cost-effective immunotherapies with potential applications across virology and oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tevogen Bio Holdings Inc.

1
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $5.4 Million Net Loss, Focuses on Immunotherapy Development

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $26.3 Million Net Loss for Fiscal Year 2025 Amid Strategic Shift

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $5.7M Net Loss in Q3 2025, Total Assets Rise to $4.5M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $5.5 Million Net Loss, Decreased R&D Expenses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $10.4 Million Net Loss in Q1 2025, Decreases Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports $13.7 Million Net Loss for 2024, Significant Increase in R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tevogen Bio Holdings Inc. Tevogen Bio Reports Financial Results for Nine Months Ended September 30, 2024, Following Merger with Semper Paratus Acquisition Corporation

Via official filing (AI summary) | over 1 year ago | 0 comments